Correlation factors and prognosis of chronic hepatitis B patients complicated with creatine kinase elevation

doi:10.3877/cma.j.issn.1674-1358.2016.01.005

Abstract

Abstract:

Objective

To investigate the correlation factors and prognosis of chronic hepatitis B (CHB) patients complicated with creatine kinase (CK) elevation.

Methods

The clinical data of CHB patients with CK elevation were collected. Ratios of patients with different anti-HBV regimens were calculated. Prognosis of patients with 3/4 grade CK elevation were analyzed. Effect of combined use of glycyrrhizis on CK level was analyzed. Correlation between CK levels and HBsAg, HBV DNA, ALT and AST were analyzed, respectively.

Results

Total of 365 CHB patients with CK elevation were enrolled. CK elevation was mainly in patients with LdT single (57.0%) or combination therapy (20.3%). Total of 30 paitents got grade 3/4 CK elevation, also mainly in patients with LdT single (66.7%) or combination therapy (20.0%), 23 patients with grade 3/4 CK elevation were followed up and show relief. One patient was diagnosed as myopathy. Combinations of NAs and glycyrrhizis had no significant influence on CK level (t′ = 1.519, P > 0.05). Correlation analysis showed that CK was related to AST (rs′ = 0.246, P < 0.001). And no correlation between CK and ALT, HBV DNA, HBsAg were found (P all > 0.05).

Conclusions

In clinical practice, CHB patients with CK elevation were mainly correlated with LdT therapy. CK monitoring should be conducted in all patients with anti-HBV therapy. Most CK elevation in CHB patients relieved. Combinations of NAs and glycyrrhizis had no significant influence on CK level.

Key words: Telbivudine, Creatine kinase, Chronic hepatitis B

Song Yang, Xiaomei Wang, Shuangbao Wang, Yingying Zhao, Huichun Xing, Jun Cheng. Correlation factors and prognosis of chronic hepatitis B patients complicated with creatine kinase elevation[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(01): 22-25.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2016.01.005

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2016/V10/I01/22

Figures/Tables 1

References 14

[1]	Kim BK, Oh J, Kwon SY, et al. Clevudine myopathy in patients with chronic hepatitis B[J]. J Hepatol,2009,51(4):829-834. URL
[2]	Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B[J]. Gastroenterology,2009,136(2):486-495.
[3]	Tak WY, Park SY, Jung MK, et al. Prevalence of muscle enzyme elevation and myopathy in chronic hepatitis B patients under long-term antiviral therapy[J]. J Hepatol,2010,52(S1):S397.
[4]	中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版)[J/CD]. 中国肝脏病杂志:电子版,2011,3(1):40-56.
[5]	Feng Q. Approach to clinical and genetic characterization of statin-induced myopathy[J]. Methods Mol Biol,2014,1175(1):67-90.
[6]	Shintani S, Murase H, Tsukagoshi H, et al. Glycyrrhizin (licorice)-induced hypokalemic myopathy. Report of 2 cases and review of the literature[J]. Eur Neurol,1992,32(1):44-51.
[7]	Luzardo L, Silvarino R, Boggia J, et al. Severe hypokalemic rhabdomyolysis. Report of six cases[J]. Rev Med Chil,2014,142(5):651-655.
[8]	Kim SJ, Khan M, Quan J, et al. Hepatitis B virus disrupts mitochondrial dynamics: induces fission and mitophagy to attenuate apoptosis[J]. PLoS Pathog,2013,9(12):e1003722.
[9]	Baharin J, Sahari NS, Lim SM. Rhabdomyolysis due to Lamivudine administration in acute viral hepatitis B infection: a case report from Malaysia[J]. Electron Physician,2014,6(3):863-867.
[10]	Yuan K, Guochun W, Huang Z, et al. Entecavir-associated myopathy: a case report and literature review[J]. Muscle Nerve,2014,49(4):610-614. URL
[11]	Lo YL, See SJ, Tan CK. Continuous single motor unit electromyographic activity in adefovir associated myopathy[J]. J Clin Neurosci,2008,15(9):1073-1074. URL
[12]	Seok JI, Lee DK, Lee CH, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA[J]. Hepatology,2009,49(6):2080-2086.
[13]	Jung M, Uddin A, Dong Y, et al. Creatine kinase elevations during 4 years telbivudine anti-hepatitis B virus (HBV) treatment are not predictive of muscle events[J]. Hepatol Int,2011,5(S1):117.
[14]	Dong YH, Uddin A, Kraev S, et al. Analyses of multiple telbivudine(LDT) studies show creatin kinase(CK) elevations do not predict muscle events(ME) during chronic hepatitis B(CHB) treatment[J]. Hepatol Int,2012,6(S1):120.

抗病毒方案	例（%）	CK最高值均值（× ULN）	CK 3/4级升高[例（%）]
未抗病毒	6（1.6）	13.247 ± 28.104	1（3.3）
LAM	6（1.6）	4.672 ± 4.934	1（3.3）
ADV	7（1.9）	1.563 ± 0.567	0（0.0）
LdT	208（57.0）	3.721 ± 4.698	20（66.7）
ETV	46（12.6）	2.111 ± 2.222	1（3.3）
IFN	2（0.5）	3.663 ± 2.120	0（0.0）
LAM + IFN	1（0.3）	10.533	1（3.3）
LAM + ADV	2（0.5）	1.324 ± 0.079	0（0.0）
ADV + IFN	1（0.3）	1.836	0（0.0）
ADV + ETV	12（3.3）	1.713 ± 0.536	0（0.0）
LdT + ADV	73（20.0）	2.902 ± 2.334	5（16.7）
LdT + ADV + IFN	1（0.3）	15.594	1（3.3）
合计	365（100.0）	3.451 ± 5.305	30（100.0）

抗病毒方案	例（%）	CK最高值均值（× ULN）	CK 3/4级升高[例（%）]
未抗病毒	6（1.6）	13.247 ± 28.104	1（3.3）
LAM	6（1.6）	4.672 ± 4.934	1（3.3）
ADV	7（1.9）	1.563 ± 0.567	0（0.0）
LdT	208（57.0）	3.721 ± 4.698	20（66.7）
ETV	46（12.6）	2.111 ± 2.222	1（3.3）
IFN	2（0.5）	3.663 ± 2.120	0（0.0）
LAM + IFN	1（0.3）	10.533	1（3.3）
LAM + ADV	2（0.5）	1.324 ± 0.079	0（0.0）
ADV + IFN	1（0.3）	1.836	0（0.0）
ADV + ETV	12（3.3）	1.713 ± 0.536	0（0.0）
LdT + ADV	73（20.0）	2.902 ± 2.334	5（16.7）
LdT + ADV + IFN	1（0.3）	15.594	1（3.3）
合计	365（100.0）	3.451 ± 5.305	30（100.0）

[1]	Qinyuan Li, Changfeng Dong, Cheng Feng, Zhiyan Li, Li Liu, Binghao He, Wei Jiang, Wenshuo Tian, Shuai Yang. Multimodal method based on elastography to stage liver fibrosis in chronic hepatitis B patients [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2022, 19(09): 976-982.
[2]	Na Shi, Wenqian Qiu, Danqing He, Chaoxue Zhang, Ping Mao, Yanting Yang. Value of transient elastography in assessing efficacy of antiviral therapy in chronic hepatitis B patients [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2022, 19(05): 428-433.
[3]	Ming Guo, Jie Yang, Zonghui Zhang, Maolin Wu. Clinical value of serum cardiac troponin I in patients with type 2 diabetes mellitus and coronary heart disease [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2019, 12(06): 389-392.
[4]	Qingtao Li, Hongyun Chen, Liyuan Tian. Relationship between serum levels of growth differentiation factor-15, heart-fatty acid-binding protein, brain natriuretic peptide and prognosis in children with pneumonia associated with heart failure [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2019, 15(06): 688-694.
[5]	Min Quan, Gaiqing Yan, Huichun Xing. Changes of soluble-Fas level in the optimal treatment of patients with chronic hepatitis B with poor antiviral response [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(01): 16-23.
[6]	Fang Xie, Xi Xiong, Chuanxia Yao, Haonan Sun, Ping Li, Maorong Wang. Clinical efficacy and influencing factors of pegylated interferon alfa-2b and nucleos(t)ide analogue in chronic hepatitis B patients with low level of hepatitis B virus surface antigen [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2022, 16(04): 247-253.
[7]	Xiuzhen Cao, Wei Yi, Fuchuan Wang, Xiumei Yang. Mother-to-child blockade with telbivudine of pregnant women infected with hepatitis B virus and the influence on the immune response to hepatitis B vaccine of infants [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2022, 16(03): 158-164.
[8]	Xuan Zheng, Bao Zhang, Shilong Li, Xiaoru Zhang. Characteristics of drug resistance mutation sites in reverse transcription polymerase region and influencing factors of drug resistance in 150 patients with different genotypes of chronic hepatitis B [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2022, 16(02): 82-89.
[9]	Shuran Qian, Jingwen Tan, Mengjie Wang, Sihang Zhang, Zhenying Yang, Yuefeng He, Hui Li. Expression and clinical significance of carcinoma-related circular RNA in patients with chronic hepatitis B virus infection [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2021, 15(02): 78-85.
[10]	Pengfei Xu, Huiling Deng, Xiaoyan Wang, Yu Zhang, Jun Wang, Yufeng Zhang, Tiantian Tang, Juan Yuan, He Song. Short-term efficacy of antiviral therapy for 6 children with chronic hepatitis B [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2020, 14(06): 518-522.
[11]	Wenjuan Shi, Yan Zhang, Zhaoxun Wang, Hong Wan. Correlation between liver pathological features and laboratory parameters of 91 patients of chronic hepatitis B with alanine aminortransferase lower than 2× upper limits of normal [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2020, 14(02): 138-143.
[12]	Renfei Zhu, Qiuqi Feng, Feng Xiao, Feng Qiu, Jianjun Wu, Fan Yang. Predictive value of serum creatine kinase for ischemia-reperfusion injury in patients with primary liver cancer undergoing hepatectomy [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2022, 11(05): 482-486.
[13]	Lichao Lian, Ziyue Fan, Xin Zhang, Li. Bai. Predictive value of combined detection of urine KIM-1, NGAL, and RBP for early renal injury in patients with chronic hepatitis B [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(04): 414-418.
[14]	Huiping Wei, Yingming Guo, Guirong Liu, Zongyou Wu, Qiuqing Weng. Application value of superoxide dismutase test in hepatitis B virus related liver disease [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(01): 21-26.
[15]	Yichai Zhang, Nan Huang, Xiaoli Liang, Min Lin. Relationship between aminotransferase and myeloid-derived suppressor cells in peripheral blood of patients with chronic hepatitis B [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2022, 10(03): 142-146.

Please choose a citation manager

Content to export